Operation Warp Speed, a US government initiative to accelerate development of 14 promising vaccine candidates against COVID-19, was launched last week (May 15, 2020). What is behind the initiative, and…
European Union (EU) health ministers met this week (May 12, 2020) to begin discussing a pharmaceutical strategy for the EU, a move originally put forth in January of this year…
The Association for Accessible Medicines, which represents generic-drug and biosimilar manufacturers in the US, put forth a blueprint to facilitate a repatriation of pharma manufacturing to the US. What does…
Industry Scorecard: New Drug Approvals and Blockbusters
Is the blockbuster model still in play or has the paradigm to more specialized drugs and smaller patient populations narrowed the blockbuster field? DCAT Value Chain Insights looks at which drugs,…
Supplying Potential COVID-19 Treatments and Vaccines
The race is on to develop treatments and vaccines against COVID-19, and so is the need to assure supply of these potential drugs and vaccines. Pharma companies are leveraging their…
Drug Development in Wake of COVID-19: Slowing or Not?
Is drug development and the drug-review process slowing due to the novel coronavirus? What do new drug approvals and updates from the top pharmaceutical companies show? Drug development and regulatory…
Small molecules dominate recent new drug approvals, but how are they factoring in the recent or potential revenue gains of the top pharma companies? DCAT Value Chain Insights examines the…
A Top 10 Watch List: Biologics and Biomanufacturing
Vaccines, historically a commoditized sector, have risen to the top of the industry’s watch list as the race for a vaccine against the novel coronavirus is on. What else is…
Manufacturing Investments: Cell and Gene Therapies
Although a niche area, cell and gene therapies represent an active area of investment by CDMOs/CMOs to build manufacturing capabilities as well as having new CDMOs/CMOs enter this sector. Which…
Tackling the Capacity Crunch in the EU from COVID-19
Nine associations, including those representing innovator and generic-drug companies and chemical manufacturers in Europe, have recommended measures to the European Commission and European Union (EU) member states to address supply…
